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The Fifth Annual Advanced Course in Cytoreductive Surgery for Ovarian Cancer and Peritoneal Surface Malignancies
was held at and sponsored by the Division of Gynecologic Oncology at the the University of California, Irvine on
Friday and Saturday, October 9-10, 2015. The workshop was comprised of didactic modules, historical treatise, an
impassioned tribute, a cadaver laboratory, and heated intraperitoneal chemotherapy demonstration. This was a
not-for-profit workshop, and registration fees were used to support course faculty travel to U.C. Irvine and to
pay for the cadavers. The original 56 available spots were filled within three weeks of the initial announcement,
prompting procurement of two additional cadavers to satisfy registration overflow and accommodate the six U.C.
Irvine fellows-in-training. While international participation in the Workshops continues to rise, we have also noted more
U.S.-trained Gynecologic Oncologists among the registrants.
Keywords: Ovarian cancer, Cytoreduction, WorkshopIntroduction: ovarian cancer – the clinical
problem
Cytoreductive surgery followed by adjuvant systemic
platinum- and taxane-based combination chemotherapy
continues to represent standard treatment of advanced
ovarian cancer. Median 10-year survival rates, however,
are still below 20 %, even as the optimal debulking para-
digm has evolved from 1 cm3 residual volume of disease
to that of complete resection (ie, microscopic residual or
R0) [1]. Enthusiasm for initially promising advancements
in therapeutic dosing, scheduling and route of delivery,
including weekly dose-dense pacliltaxel [2, 3] and com-
bined intraveneous/intraperitoneal chemotherapy [4, 5],
has been curtailed in recent months [6–8]. Furthermore,
despite eight positive, phase III, randomized trials in-
volving five different anti-angiogenesis agents [9], vascu-
lar endothelial growth factor inhibition has only been
able to significantly improve progression-free survival,
not overall survival (OS). Although supporters of antivas-
cular strategies continue to regard PFS as a valid endpoint
because post-progression therapy cannot be controlled inCorrespondence: ktewari@uci.edu
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(http://creativecommons.org/publicdomain/zethe clinical trial setting [10], recent translational work
suggests that the genomic instability which underlies
ovarian carcinoma produces a phenotype comprised
of different subgroups (eg., immune, pro-angiogenic)
that limit the reach of the presumably wide net cast
by anti-angiogenesis therapy [11]. The concept of
oncogene addiction does not apply to this disease as
prevalent driver mutations have not yet been identified
[12]. Current research aims to identify and exploit somatic
and germline homologous recombination deficiency mu-
tations (eg, BRCA1, BRCA2, RAD51, etc.) via the synthetic
lethality conferred through poly-ADP-ribose polymerase I
inhibition [13–20]. In addition, strategies to break im-
mune tolerance using programmed cell death ligand 1 and
programmed death 1 inhibitors are being investigated
[21–23].
Due to the absence of validated predictive biomarkers,
only clinical and prognostic biomarkers are available to
inform discussions with patients. Age, FIGO stage,
grade, histology, performance status, volume of residual
disease following cytoreductive surgery, and possibly
time to initiation of adjuvant chemotherapy and rapidity
of response to systemic therapy based on serial biochem-
ical and radiographic analyses represent powerfulle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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status can be modified through medical and nutritional
intervention, the time to initiation of chemotherapy is
dependent on multiple factors including access to care,
insurance authorizations, and perioperative sequelae.
Thus, the only prognostic factor which is under control
of the oncologist is the volume of tumor residual follow-
ing cytoreductive surgery.
Workshop planning
The Fifth Annual Cytoreductive Surgery Workshop for
Advanced Ovarian Carcinoma and Peritoneal Surface
Malignancies was held in Orange County, California.
Didactics were delivered at the Surf & Sand Hotel in
Laguna Beach and cadaver dissections with demonstra-
tion of cardinal advanced cytoreductive surgical strategy
were performed at the University of California, IrvineFig. 1 Global and U.S. Interest in surgical workshops for advanced ovarianMain Campus in Irvine. The assembled faculty included
course director Robert E Bristow, MD from the home insti-
tution (radical oophorectomy), Krishnansu S. Tewari, MD
(also from UC Irvine; extrapelvic colon and bowel), Scott M
Eisenkop from the Women’s Cancer Center in Sherman
Oaks, CA (retroperitoneum), David Imagawa from UC
Irvine (liver), William A. Cliby from the Mayo Clinic in
Rochester, MN (spleen, diaphragm), Cyril W. Helm from St.
Louis University Hospital (HIPEC), and Dennis S. Chi from
Memorial Sloan-Kettering Cancer Center in New York
(VATS), Similar to previous years, there was representation
from the nations of six continents. Interestingly, while the
international attendance which started off relatively high in
2011, continues to grow, this year there were many more
attendees from the United States (Fig. 1, Table 1).
Didactics were subdivided into three components: 1) a
history of the evolution of cytoreductive surgerycancer
Table 1 Six years of cytoreductive surgery workshops
Year Course site # Attendees # Countries represented
2011 U.C. Irvine Medical Center, Orange, CA 25 12
2012a St Louis University Medical Center
2013 U.C. Irvine Main Campus (Irvine)b 36 18
2014a Newcastle on Tyne, United Kingdom
2015 U.C. Irvine Main Campus (Irvine)b 59 26
2016c Newcastle on Tyne, United Kingdom
Philippine Society of Gynecologic Oncology, Manila, Philippines
U.C. Irvine Main Campus Fellows-in-Training Course
aSatellite workshops
bDidactics given at the Surf & Sand Hotel in Laguna Beach, CA
c2016 workshops in Manila and in the UK have only recently been completed and therefore final registration data concerning number of participants and
demographics is not yet available; the Fellows' Workshop is not scheduled to take place until November
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origins of cytoreduction for ovarian cancer (now regarded
as the “2nd Law of Cytoreduction”); 2) lectures on surgical
innovations and strategic planning in systematic anatomic
manner based on intra-abdominal and extra-abdominal
spread patterns of disease; 3) tribute to a pioneer in the
field of surgery. At the 14 cadaver stations, faculty rotated
among attendees to illustrate the principles of eight
anatomic surgical procedures required to accomplish an
R0 designation at completion of cytoreduction.
Reiteration of the First Thesis
Introduced by faculty member, KS Tewari, at the 1st
Workshop on November 4, 2011, the concept of cytore-
duction for ovarian cancer evolved over three periodsFig. 2 Johns Hopkins University. a John Singer Sargent’s The Four Doctors
(pathologist & Dean), Osler (internist), Halstead (surgeon), and Kelly (gyneco
Hopkins Medical Class of 1892 with Dr(s) Kelly and Clark seated in the fron
Public Domainencompassing nearly 200 years [24]. Beginning with
Ephraim McDowell’s (1771-1830) first oophorectomy
performed on 45-year old Jane Todd Crawford (1763-
1842) on his kitchen table on Christmas Day, 1809, a
surgical masterpiece was created for which McDowell
was named the Father of Abdominal Surgery [25]. At-
tempts at oophorectomy or ovarian cystectomy preced-
ing McDowell’s time are not in short supply (including
forays into antiquity and even Robert Houston’s 1701
“puncture” of an ovarian cyst [26]), but McDowell was
the first to safely remove an ovarian tumor and describe
his technique in detail. The second period encompassed
the idea that surgery could be performed even in the set-
ting of metastatic disease, with proponents including Joe
Vincent Meigs (1892-1963) of Boston Hospital [27],(1906) depicting the Founding Professors (left to right): Welch
logist). b Early photograph of The Johns Hopkins Hospital. c Johns
t row (third and second from the right, respectively). All images in the
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pelvis [28], and Hugh R. K. Barber (1918-2006) and
Alexander Brunschwig (1901-1969) who used pelvic
exenterative procedures (designed for women suffering
from central, isolated recurrence of cervical cancer fol-
lowing radiotherapy) to treat 22 women with advanced
and recurrent ovarian cancers [29]. The third and final
period of the evolution of the concept of cytoreduction
and inherent validity in advanced disease encompasses
the 1973 report by McGrath on the survival advantage
afforded patients with abdominal Burkitt’s lymphoma
who underwent extensive disease resections [30], the
landmark study by Griffiths from 1974 in which the sur-
geon reported that among 102 consecutive cases of ad-
vanced ovarian cancer, those patients in whom residual
disease greater than 1.5 cm in maximal diameter was left
in the abdominal cavity were invariably dead within
2 years as compared to the 20 % 5-year survival rate
conferred by tumor residuals under 1.5 cm [31], and
finally, the watershed event by Bristow et al. in which a
meta-analysis of 81 ovarian cancer cohorts (nearly 7,000
patients) treated with platinum-based chemotherapy
demonstrated that the most important determinant of sur-
vival was maximal cytoreduction with each 10 % increase
in tumor resection associated with a 5.5 % increase in me-
dian survival time [32]. This chronology appears in greater
detail in our first Workshop Report [24]. The First Law of
Cytoreduction is concerned with the temporal aspects and
holds that the evolution traversed three distinct periods
involving oophorectomy, surgery in the setting of meta-
static disease, and validation of surgical effort to bring the
residual disease volume to no visible tumor (ie, R0).The Road to Baltimore (New Thesis or 2nd Law)
The rationale for cytoreduction is supported by several
hypotheses concerning intrinsic tumor drug resistance
(which is independently described by both the Goldie
Coldman hypothesis for acquisition of somatic muta-
tions and Bayes Theorem) by which large areas of dis-
ease harboring chemoresistant clones are resected [24].
Increased tumor growth fraction (described according to
Gompertzian cell kinetics) occurring after surgery shut-
tles resting phase G0 cells into the cell cycle and thereby
makes them more vulnerable to cycle-specific antineo-
plastic agents. Maximal cytoreduction also results in in-
creased drug perfusion, a lower likelihood of developing
acquired drug resistance, and enhanced host immuno-
logic competence. To date the best outcomes among
women with advanced ovarian cancer appear to be in
the group of patients who can withstand cytoreductive
surgery to optimal disease status (ie., low volume re-
sidual < 1 cm or R0) and six cycles of combined
intraperitoneal-intravenous chemotherapy.Optimal cytoreduction and/or complete resection in
the abdomen and pelvis is accomplished through radical
pelvic surgery and in many cases upper abdominal pro-
cedures with complete parietal and visceral peritonect-
omy [33]. Interestingly, radical pelvic surgery was
initially applied to cervical cancer. Although surgeons in
Germany (A. K. Mackenrodt (1859-1925)) and in Austria
(eg., Frederick Schauta (1849-1919), vaginal approach),
Ernst Wertheim (1864-1920, abdominal approach) were
developing the technique of radical hysterectomy for
cervical cancer during the latter part of the 19th Century
[34], it was in the United States, specifically in Baltimore,
Maryland, that a formal treatise was prepared.
The Johns Hopkins University was founded in 1876
and named after its first benefactor the American entre-
preneur, abolitionist, and philanthropist, Johns Hopkins.
With the completion of Johns Hopkins Hospital in 1889
and the medical school in 1893, the university’s research
focus attracted faculty members with international repu-
tations who would ultimately emerge as major figures in
academic medicine. Among the “Big Four” founding
professors of Johns Hopkins Hospital (Fig. 2a-b) was Sir
William Osler, 1st Baronet (1849-1919), the internist
who would bring medical students out of the lecture hall
for bedside clinical training and become known as the
“Father of Modern Medicine”. William Henry Welch
(1850-1934) was the pathologist (and bacteriologist) and
served as the first Dean of the Johns Hopkins School of
Medicine. William Stewart Halsted (1852-1922) was the
surgeon who emphasized strict aseptic technique and
developed the en bloc radical mastectomy for breast can-
cer [35]. Finally, Howard Atwood Kelly (1858-1943) was
the gynecologist who had been trained by James Marion
Sims (1813-1883), the “Father of Modern Gynecology”
who developed the Sims speculum and the surgical tech-
nique for repair of vesicovaginal fistula due to
obstructed childbirth. Kelly himself is credited for having
established gynecology as a distinct specialty and devel-
oping new surgical instruments and surgical approaches
to gynecologic diseases.
John Goodrich Clark (1867-1927) (Fig. 2c) had trained
at the University of Pennsylvania and interned at a local
Philadelphia hospital before coming to Johns Hopkins.
He had originally been granted a residency position with
Osler, but upon arrival he was told that that position
had been committed to another physician. Fortunately,
Kelly had an opening, and so through a quirk of fate,
Clark changed career paths abruptly from internal medi-
cine to gynecology [34]. Kelly assigned Clark the task of
developing a more radical approach to the treatment of
cervical cancer. At pathologic examination, Clark noted
that in 15 of 20 cases, the disease had extended beyond
the margins of resection. Having become influenced by
the surgical doctrines of Halstead (Fig. 3a), Clark began
Fig. 3 Evolution of en bloc and cytoreductive surgery. a Halsteadian principle of radical mastectomy [35]; b Clark’s radical hysterectomy for
carcinoma of the cervix [37]. c Magrath’s demonstration of improved survival with surgical resection of abdominal Burkitt’s lymphoma [30]; d
Original table from Griffith’s seminal report on the impact of residual disease following surgery and survival in ovarian cancer [31]; e Bristow’s
meta-analysis demonstrating that each additional 10 % effort at maximal cytoreduction confers a 5.5 % survival advantage in advanced ovarian
cancer treated during the platinum era [32]; f Overall survival curves from GOG 172 demonstrating 16 month improvement among women who
had undergone optimal cytoreduction followed by intravenous-intraperitoneal chemotherapy [4]
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bloc radical hystererctomy for cervical cancer [34] (Fig. 3b).
The difference between Clark and his more senior
European contemporaries (eg., Mackenrodt, Schauta,
Wertheim), was in rationale, thesis, and methodology [36].
John Hopkins Hospital is where Robert E Bristow (cur-
rently Chairman of Obstetrics & Gynecology at UC Irvine
Medical Center in Orange, California) began collectingdata on not only the performance of radical hysterectomy
with radical oophorectomy (which encompassed in most
cases a low anterior resection) for advanced ovarian can-
cer, but the performance of numerous other upper ab-
dominal operations required to bring the residual disease
burden down to zero (eg., splenectomy, full-thickness dia-
phragm resection, porta hepatis surgery, supra-renal
lymphadenectomy, video-assisted thorascopic surgery
Tewari Gynecologic Oncology Research and Practice  (2016) 3:10 Page 6 of 11(VATS), etc.) [37]. As stated earlier, this work culminated
in what remains a heavily cited paper in the field, specific-
ally Bristow’s meta-analysis performed while in Baltimore
and published in 2002 [32] (Fig. 3d).
Finally, John Hopkins medical oncologist, Deborah
Armstrong, served as the Study Chair and Principal In-
vestigator for GOG protocol 172, the phase III random-
ized trial of intravenous chemotherapy vs intravenous-
intraperitoneal chemotherapy which demonstrated a 16-
month OS advantage in the combined therapy arm [4]
(Fig. 3f ). Regional therapy exploits both the prolonged
confinement of disease within the peritoneal cavity and
the steep dose-response relationship observed for many
cytotoxic agents, allowing for a slower rate of drug
clearance from the peritoneal to systemic compart-
ments, ultimately creating a concentration differential
across the peritoneal-plasma barrier that favors the
peritoneal cavity [24].
GOG 172 was actually the third phase III randomized
trial by the GOG to demonstrate a survival advantage
with intraperitoneal chemotherapy, but all three studies
had been subject to reasonable scrutiny, with GOG 104
(published in 1996 [38], the same year that GOG 111
was published and demonstrated the superiority of com-
bining paclitaxel with cisplatin over cyclophosphamide
plus cisplatin [39]) not including taxanes, and with GOG
114 (published in 2001) [40] being criticized for intra-
venous platinum dose escalation in the intraperitoneal
arm (ie., prior to intraperitoneal therapy patients re-
ceived 2 cycles of intravenous carboplatin at AUC 9).
Not only was GOG 172 marred by significant toxicity
which only permitted 40 % of patients on the combined
intravenous-intraperitoneal arm to receive all six cycles
of adjuvant therapy, but the schedule of paclitaxel on the
intravenous-intraperitoneal arm (24 h intravenous paclil-
taxel (135 mg/m2 BSA) on day 1 followed by intraperito-
neal paclitaxel (60 mg/m2 BSA) on day 8) suggested that
weekly dose-dense taxane therapy could have accounted
for the superior results. Despite these criticisms, a
follow-up combined analysis of GOG 114 and GOG 172
by Tewari et al., does attest to the long-term survival (ie,
9 years) benefit of combined intravenous-intraperitoneal
therapy [5]. Recent presentations at the 2016 Annual
Meeting of the Society of Gynecologic Oncology (ie.,
GOG 252), have been disappointing with respect to in-
traperitoneal chemotherapy, with GOG 252 not having
a proper control arm making the entire trial essentially
uninterpretable [7]. Nevertheless, given the long-
standing shortcomings of the three previous IV-IP vs
IV phase III randomized trials described above, the
negative results of GOG 252 have added to the growing
disenchantment with IP therapy that has gained trac-
tion with many oncologists who treat women with
advanced disease.Criticisms aside, it is clear that John Hopkins Hospital
in Baltimore has served as fertile ground for what is
considered the treatment paradigm for advanced ovarian
cancer. The Second Law of Cytoreduction concerns it-
self with geospatial constraints and holds that the devel-
opment of radical pelvic surgery, together with upper
abdominal procedures and adjuvant regional therapy
took place at ground zero in Baltimore.
Tribute to Dr. Francis D. Moore (1913-2001)
At the 2015 Cytoreductive Surgery Workshop a tribute
to Dr Francis Moore was made during the didactic com-
ponent (Fig. 4a). His classic books, Metabolic Response
to Surgery (1949) and Metabolic Care of the Surgical Pa-
tient (1959) (Fig. 4b), are regarded as masterpieces that
according to Judah Folkman (1933-2008), the pioneer of
angiogenesis and anti-angiogenesis therapy [41], changed
the thinking of surgeons throughout the world and re-
duced suffering and mortality of their patients [42]
(Fig. 4c). Before Moore, surgeons concentrated on im-
proving their craft to effect the local anatomic changes
necessary to treat disease, but they remained perplexed
by the body’s physiologic response to the trauma of sur-
gery. Surgeons during the first half of the 20th Century
did not understand how to optimize the physiologic sta-
tus of their patients before surgery. A perfect anatomical
operation could be followed by disastrous complications
or death from a low level of circulating sodium chloride
or magnesium, or a high level of potassium chloride, or
an undetected loss of plasma water [43]. Dr Moore was
among the first translational scientists and his studies
carried out between the physiology laboratory and the
patient’s bedside culminated in his classic books which
were regarded as the “Bible” of surgery for five genera-
tions of surgeons. The book was so well-written that in
his lifetime, no updated/expanded edition needed to be
written. At the 2015 Workshop, the purpose of the trib-
ute was to recognize Moore’s trailblazing work as that
fundamental body of knowledge which has provided
gynecologic oncologists with the knowledge base and
confidence to pursue advanced surgical resections in
women with ovarian cancer (Fig. 4b).
Surgery for Ovarian Cancer – A Surgical Atlas
The 2015 Workshop was held to coincide with publica-
tion of the 3rd edition of Surgery for Ovarian Cancer,
which continues to be edited by Bristow RE, Karlan BY,
and Chi DS. The 3rd edition is noteworthy for allowing
access to the entire text as a VitalSource® ebook and
contains instructions for creating a VitalSource Book-
shelf upon redemption of the code contained on the
scratch-off panel on the inside front cover. Internet links
to high definition video illustrating many of the surgical
procedures presented at the Workshop are also
Fig. 4 Understanding the physiologic responses to surgery has allowed surgeons to safely perform the multiple surgical procedures required at
times to completely cytoreduce women with advanced ovarian cancer. a Dr. Francis D. Moore (1913-2001); b: Metabolic Care of the Surgical
Patient by Moore; b Dr. Moore on the cover of Time Magazine, May 1963
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pants were provided a copy of this text book.
Cadaver stations
Coincident with the adaptation of surgical technique
within the confines of this disease along with incorp-
oration of procedures from other disciplines, cadaver
dissections continue to evolve. For example, the at-
tendees at the 2011 workshop were notably interested
in the performance of low anterior resection with
end-to-end anastomosis, splenectomy, and peritoneal
stripping from the diaphragm. In 2015, cadaveric sta-
tions catering to the performance of the following
were most popular:
A. Radical oophorectomy (key points):
a. The en bloc specimen includes the uterus, adnexae,
anterior pelvic peritoneal tumor, cul-de-sac tumor,
and rectosigmoid colon, all contained within the
peritoneal bag to leave the pelvis macroscopically
tumor-free (Fig. 5a).
b. The integrity of the rear admiral’s circular end-to-
end anastomosis is demonstrated by the production
of two symmetrical, intact donuts and a negative
bubble test.
B. Splenectomy with distal pancreatectomy (key
points):
a. Identification of the left gastric vessels and the
inferior mesenteric vein (IMV) (Fig. 5b).
b. Umbilical tape placed to the left of the IMV
c. Individual ligation of the splenic artery and veind. En bloc resection of distal pancreas with spleen by
dividing the tail distal to ligated splenic vessels
e. Distal pancreas closed with running stitch of delayed
absorbable suture followed by reinforcing layer of
2-0 silk mattress stitches.
C. Liver mobilization to allow full-thickness resection
of the right diaphragm (key points):
a. Following division of the round ligament, the
falciform ligament is divided towards its apex where
it bifurcates into the coronary ligament
b. Incision of the coronary ligament exposes the right
hepatic vein and inferior vena cava and the
dissection is maintained superficial to these vessels
(Fig. 5c)
c. The liver is drawn inferiorly and medially by
releasing the ligamentous attachments of the left
lobe
d. In sequence, the left triangular ligament, the anterior
and posterior layers of the left coronary ligament,
the hepatogastric ligament, the anterior layer of the
right coronary ligament, and the right triangular
ligament are divided, exposing the right paracolic
gutter and Morison’s pouch.
e. The incision for diaphragm resection should include
a 0.5-1.0 cm margin and run parallel to the path of
the branching phrenic nerve.
In addition to the stations listed above, the 2015
Workshop included cadaver dissections to demonstrate
suprarenal aortic lymphadenectomy, resection of porta
hepatis disease, and the Pringle maneuver in which the
Fig. 5 Highlights from Cadaver dissections at the 2015 Surgery Workshop: a radical oophorectomy; b splenectomy with distal pancreatectomy; c
hepatic mobilization; d Pringle maneuver. Figure 4a from Bristow RE, et al. J Am Coll Surg 2003; b-d from Surgery for Ovarian Cancer, 3rd Edition,
Bristow RE, Karlan BY, Chi DS (eds), Taylor & Francis Group, 2015. All images used with permission
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and the thumb through a defect in the gastrohepatic
ligament to access the porta hepatis, allowing for total
inflow occlusion via an atraumatic clamp or silastic ves-
sel loop to prevent unnecessary blood loss during wedge
and/or hepatic resections (Fig. 5d). Both heated intraper-
itoneal chemotherapy (HIPEC) and video-assisted thora-
scopic surgery (VATS) were also featured in the cadaver
laboratory, with the latter representing a new addition to
the 2015 Workshop.
Discussion
The discipline of surgery requires life-long learning. In
the subspecialty of Gynecologic Oncology, this principle
has been best exemplified by the introduction of minim-
ally invasive surgery into the management of clinicalstage I endometrial cancer, FIGO stage I cervical cancer
(including lesions amenable to fertility-preserving radical
trachelectomy), and select adnexal masses. Some prac-
ticing Gynecologic Oncologists had little or no laparo-
scopic training during fellowship, and many had no
robotics training. Minimally invasive workshops held by
the American Association of Gynecologic Laparoscopists
and by the Society of Gynecologic Oncology in col-
laboration with industry partners (eg., Intuitive Surgi-
cal, Ethicon, Covidien, etc.) have helped disseminate
the knowledge of minimally invasive surgery through-
out the subspecialty and brought many surgeons up
to speed with this essential treatment modality.
While the principles of cytoreductive surgery are
taught in Gynecologic Oncology fellowship training pro-
grams throughout the world, the demonstration of
Fig. 6 The Fifth Annual Cytoreductive Surgery Workshop (2015). a Workshop faculty (from left to right): Dr(s) Cliby, Bristow, Helm, Eisenkop, and
Chi; b An astonished Ramirez Escobar attempts to dissect a cadaver in the laboratory; c Dr. Tewari presents his thesis, The Road to Baltimore,
during didactics; d Participants (attendees, faculty, and UCI fellows) seen outside of the cadaver dissection laboratory
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plish optimal debulking status or even an R0 resection ap-
pears to vary to some degree. In the EORTC randomized
trial of primary surgery vs neoadjvuant chemotherapy,
Vergote et al. reported that the hazard ratio (HR) for
death in the group assigned to neoadjvuant chemotherapy
followed by interval debulking surgery, (as compared with
the group assigned to primary debulking surgery followed
by chemotherapy), was 0.98 (90 % CI, 0.84-1.13; p-0.01 for
non-inferiority) and the HR for PFS was 1.01 (90 % CI,
0.89-1.15) [44]. Although postoperative rates of adverse ef-
fects and mortality tended to be higher after primary
debulking than after interval cytoreduction, this study
raised a number of controversies, particularly regarding
the quality of debulking surgery. While complete resection
of all macroscopic disease (at primary or interval surgery)
was the strongest independent variable in predicting OS,
only 41.6 % of patients were rendered optimally debulked
to 1 cm or less of residual tumor following primary cytor-
eduction, as compared to 80.6 % of patients after interval
cytoreduction. Similarly, in the MRC CHORUS Trial
which also demonstrated significant non-inferiority be-
tween primary and interval cytoreduction arms, only 25 %
of patients in the primary surgery cohort were left with <
1 cm residual disease [45]. These results for optimal cytor-
eduction rates are much lower than what is reported by
many U.S. centers. For these reasons it was not surprising
that beginning with the First Annual Cytoreductive Sur-
gery Workshop in 2011 that attendees were registering
from around the world, with each succeeding Workshop
receiving even more participation from our global
partners.
Interestingly, each succeeding workshop has also been
met with increased registration from graduates of
American Board of Obstetrics & Gynecology certified
training programs. The high numbers of U.S. partici-
pants in the 2015 workshop (Fig. 6) may be the result of
the aftermath following plenary presentation of GOG
data at the 2015 SGO Annual Meeting in which notable
discrepancies were reported between surgeon’s assess-
ment of cytoreduction status and pre-treatment imaging
on a U.S.-led phase III randomized clinical trial of anti-
angiogenesis therapy for newly diagnosed advanced
ovarian carcinoma [46]. Enthusiasm for these types of
activities has led directly to our first Cytoreductive Sur-
gery Workshop designed specifically for fellows-in-
training. All 24 spots for this 2016 Fellows Cytoreductive
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